Cambridge, UK, 21 March 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, today announces that Dani Bach has been appointed as Non-Executive Director of the Company with immediate effect. Dani replaces Rob Woodman as the representative for IP Group plc., now one of the largest shareholders of the Company.
Dani has extensive investment experience in areas ranging from medical devices to protein therapeutics. He is currently Partner, Life Sciences at IP Group, having joined Touchstone Innovations in January 2016.
Prior to this, he was Managing Partner at Aravis, where he co-led the design of the investment strategy, fund raising and investment process. Dani also previously worked at Index Ventures, where he helped to build companies such as Levicept and Versartis.
Dani holds a PhD in Molecular Biology from the University of Barcelona and an executive MBA from the Escuela de Organización Industrial (Madrid).
Kevin Johnson, Chairman of the Board of Directors at Crescendo Biologics, said:
“Dani is a great new addition to Crescendo. Having known him for a long time, I am confident that his substantial experience within healthcare investment will bring considerable value to the Board.”
Dani Bach, Non-Executive Director, also commented:
“Crescendo is developing an exciting pipeline of highly differentiated, multi-functional Humabody® therapeutics. I look forward to bringing my expertise to the role, in order to help progress the therapeutic potential of these novel products.”
Dr Peter Pack, CEO of Crescendo, added:
“Dani’s relevant experience will be a great asset to the Board of Directors, especially with his involvement in building other biopharmaceutical companies such as Levicept. I would also like to thank Rob Woodman for his outstanding contribution to the Board since 2013 and wish him well for the future.”
This appointment continues to strengthen the specialist knowledge and sector experience of Crescendo’s Board of Directors.
About Crescendo Biologics Ltd
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated mono- and multifunctional Humabody® therapeutics in oncology with a proprietary pipeline focus on innovative targeted T-cell approaches.
At the heart of its proprietary pipeline, Crescendo has developed CB307, a novel bispecific PSMA-targeted T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting any of a range of alternative tumour-specific markers.
The Company’s ability to develop mono- and multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel biology and superior biodistribution. This results in larger therapeutic windows compared to conventional IgG-approaches.
Crescendo is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships, including multi-functional immuno-oncology modulators and Humabody® Drug Conjugates (HDCs), the next generation of ADCs. However, Humabody®-based formats can be applied across a range of non-cancer indications.
Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, IP Group, Takeda and Astellas.
For more information, please visit the website: www.crescendobiologics.com
Issued for and on behalf of Crescendo Biologics by Instinctif Partners.
For more information please contact firstname.lastname@example.org.